Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.

Engers JL, Rodriguez AL, Konkol LC, Morrison RD, Thompson AD, Byers FW, Blobaum AL, Chang S, Venable DF, Loch MT, Niswender CM, Daniels JS, Jones CK, Conn PJ, Lindsley CW, Emmitte KA
J Med Chem. 2015 58 (18): 7485-500

PMID: 26335039 · PMCID: PMC4809247 · DOI:10.1021/acs.jmedchem.5b01005

Previous preclinical work has demonstrated the therapeutic potential of antagonists of the group II metabotropic glutamate receptors (mGlus). Still, compounds that are selective for the individual group II mGlus (mGlu2 and mGlu3) have been scarce. There remains a need for such compounds with the balance of properties suitable for convenient use in a wide array of rodent behavioral studies. We describe here the discovery of a selective mGlu3 NAM 106 (VU0650786) suitable for in vivo work. Compound 106 is a member of a series of 5-aryl-6,7-dihydropyrazolo[1,5-a]pyrazine-4(5H)-one compounds originally identified as a mGlu5 positive allosteric modulator (PAM) chemotype. Its suitability for use in rodent behavioral models has been established by extensive in vivo PK studies, and the behavioral experiments presented here with compound 106 represent the first examples in which an mGlu3 NAM has demonstrated efficacy in models where prior efficacy had previously been noted with nonselective group II antagonists.

MeSH Terms (18)

Allosteric Regulation Animals Anti-Anxiety Agents Antidepressive Agents Brain Calcium Dogs Heterocyclic Compounds, 2-Ring Humans Madin Darby Canine Kidney Cells Mice Microsomes, Liver Permeability Pyridines Rats Receptors, Metabotropic Glutamate Stereoisomerism Structure-Activity Relationship

Connections (3)

This publication is referenced by other Labnodes entities: